Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.44 |
| ▸ | FNTB | P49356 | 8/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2381616 | 0.89 | FNTA (0.47) | FNTAFNTBPGGT1BKCNH2GRM2 | |
| SCHEMBL3501112 | 0.84 | FNTA (0.56) | FNTAFNTBPGGT1BGRM2 | |
| Trifluoroacetic Acid SCHEMBL8162228 | 0.84 | FNTA (0.43) | FNTAFNTBPGGT1BKCNH2 | |
| Hydrochloric Acid SCHEMBL8539293 | 0.84 | FNTA (0.56) | FNTAFNTBPGGT1BGRM2 | |
| SCHEMBL4405093 | 0.83 | FNTA (0.40) | FNTAFNTBPGGT1BKCNH2GRM2 | |
| SCHEMBL3687066 | 0.75 | FNTA (0.59) | FNTAFNTBPGGT1BKCNH2GRM2 | |
| SCHEMBL445626 | 0.75 | FNTA (0.59) | FNTAFNTBPGGT1BKCNH2GRM2 | |
| SCHEMBL3517007 | 0.73 | FNTA (0.50) | FNTAFNTBPGGT1BKCNH2 | |
| Hydrochloric Acid SCHEMBL7818562 | 0.72 | FNTA (0.54) | FNTAFNTBPGGT1BKCNH2GRM2 | |
| SCHEMBL5583314 | 0.72 | FNTA (0.72) | FNTAFNTBPGGT1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744751-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005089502-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885PGGT1B 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.